AzTrials
AzTrials

Hereditary Transthyretin AmyloidosisLOCUSNCT06414746

Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia

An observational study of Hereditary Transthyretin Amyloidosis and Carpal Tunnel Syndrome, run by AstraZeneca at 13 sites in Russia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This is a multicenter observational study consisting of retrospective and prospective phases. The retrospective phase will entail secondary data collection from electronic or paper medical records of patients who underwent surgery for CTS to assess their probability of having ATTR PN. Read more about this study

Who is it for?
Ages 18 years and older
How many people
721 participants
Where
13 sitesRussia
Study dates
29 Dec 2023to 12 Jun 2025
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: This multicenter observational study will retrospectively include 1300 consecutive adult patients diagnosed with CTS and having bilateral involvement in Russia from the earliest date of diagnosis to a later one within the specified time period who are observed and monitored at 20 participating sites, including approximately ~800 patients with CTS and high suspicion of having ATTR PN who will be enrolled in the prospective phase.

Who may be able to join

  • for the retrospective phase are:
  • Patients with the established diagnosis of CTS.
  • Bilateral involvement of carpal tunnel established between the 1st January 2021 and the 31st December 2024 (both patients who underwent CTS surgical intervention and without it are enrolled).
  • Age ≥ 18 years at the time of CTS diagnosis.
  • Provided written informed consent for the prospective phase of the study (including molecular genetic testing).
  • Presence of ≥1 of the following features (red flags):
Show all 9Show fewer
  • CIDP or polyneuropathy of unknown etiology in the family history; b. Spinal canal stenosis of the lumbar region; c. Autonomic dysfunction, defined by the presence of ≥1 of the following symptoms - i. Gastrointestinal complaints (constipation, chronic diarrhea, or both); ii. Erectile dysfunction; iii. Orthostatic hypotension; d. Gait disorders; e. Sweating disorders, anhidrosis. f. Paresthesia and burning of the skin of the distal extremities g. Distal symmetrical paresis h. Hypotrophy and hypotension of limb muscles, areflexia i. Biceps tendon rupture j. Aortic valve stenosis k. Diagnosis of HFpEF
  • Unexplained weight loss ≥5 kilos at any timepoint since the onset of symptoms of CTS; m. Left ventricular hypertrophy (based on electro- or echocardiographic criteria documented in the patient's medical record); n. Heart rhythm disorders; o. Renal abnormalities, defined by ≥1 of the following features - i. Documented diagnosis of chronic kidney disease (CKD); ii. Decreased estimated glomerular filtration rate (eGFR <60 mL/min/1.73m2); iii. Increased serum creatinine (SCr) above reference range of the local laboratory; iv. Albuminuria (≥30 mg/g of creatinine or ≥30 mg/24h); v. Proteinuria (according to urinalysis results); p. Ophthalmology disorder defined by ≥1 of the following features - i. Vitreous body inclusions (opacification); ii. Glaucoma; iii. Pupillary disorders; iv. Vitrectomy
  • Absence of previously established ATTR PN diagnosis (ICD-10 code Е85.1, "Neuropathic hereditary familial amyloidosis").

Who cannot join

  • Participation in any interventional trial within the period since identification of bilateral involvement of carpal tunnel until the end of current study.
  • The following criteria apply for non-inclusion of patients into the prospective part of the study:
  • Previously performed TTR genetic testing;
  • Verified B12 deficiency;
  • History of alcohol abuse according to the patient's medical record.

Trial locations and contacts

13 sites in 1 country.

13 sites in 1 country

Russia13 sites

  • Research Site

    Arkhangelsk

  • Research Site

    Barnaul

  • Research Site

    Chelyabinsk

  • Research Site

    Irkutsk

  • Research Site

    Kazan'

  • Research Site

    Krasnodar

  • Research Site

    Moscow

  • Research Site

    Nizhny Novgorod

  • Research Site

    Rostov-on-Don

  • Research Site

    Saint Petersburg

  • Research Site

    Samara

  • Research Site

    Ufa

  • Research Site

    Yekaterinburg

Other trials in Russia

About this study

Official title: A Multicenter Observational Retrospective-prospective Study of Prevalence, Clinical Characteristics of Hereditary Transthyretin Amyloidosis Polyneuropathy in Russian Patients Undergoing Surgery for CTS in Real Clinical Practice

This is a multicenter observational study consisting of retrospective and prospective phases. The retrospective phase will entail secondary data collection from electronic or paper medical records of patients who underwent surgery for CTS to assess their probability of having ATTR PN.

Read the detailed description

ATTR PN is a genotypically, phenotypically and geographically variable disease with a poor prognosis, albeit available disease-modifying drugs can change the disease trajectory. Thus country-specific epidemiologic data collection and identification of early stage PN, including previously misdiagnosed patients, is crucial to improve outcomes and quality of life. However, no observational studies on the epidemiology of ATTR PN in the whole Russian population, or in patients with CTS, have been performed.

Therefore, there is a need to conduct a large-scale observational study to determine the prevalence of ATTR PN in Russia, obtain information on patients' clinical characteristics, and determine their medical needs.

The approaches to diagnosis of ATTR PN in Russia over the past few years have been characterized by the use of heterogenous methods, partially explained by the lack of availability of molecular genetic testing, which is essential to diagnose the presence of pathogenic mutation in patients with hereditary ATTR PN. Thus, recent introduction of such tests into routine clinical practice may allow to assess reliable epidemiologic data including estimation of true ATTR PN prevalence among patients with CTS, which can often be the first manifestation of the disease. Earlier recognition, in turn, may lead to timely treatment initiation and change in the prognostic outlook of ATTR PN patients.

In order to assess the prevalence of ATTR PN in patients undergoing surgery for CTS in Russia this study will retrospectively include patients with the diagnosis of CTS undergoing surgery between the 1st January 2021 and the 1st September 2024. Suspicion of ATTR PN will be assessed in each case, and diagnostic tests (comprehensive neurological examination including nerve conduction study (NCS) combined with molecular genetic testing) to confirm or exclude the disease will be conducted prospectively in eligible patients. In addition to that, clinical features, concomitant manifestations, and diagnosed genotypes will be analyzed to examine characteristic ATTR PN patient profiles in the Russian Federation.

Keywords
ATTR PN, CTS, PN, carpal tunnel syndrome, polyneuropathy, amyloidosis
Medical subject headings
Amyloidosis, Hereditary, Transthyretin-Related, Carpal Tunnel Syndrome, Polyneuropathies, Amyloidosis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To define the prevalence of ATTR PN in patients diagnosed with CTS and having bilateral involvement in routine clinical practice in the Russian Federation.

    In order to achieve primary objective, the proportion of patients with confirmed diagnosis of ATTR PN (presence of TTR gene mutation according to the results of molecular genetic testing and clinical symptoms and/or signs of polyneuropathy) among those diagnosed with CTS and having bilateral involvement will be calculated.

    Measured: Up to 12 months

Secondary outcomes (68)

  1. To assess general demographic characteristics of patients with ATTR PN in Russia - Mean age (years) at the onset of CTS symptoms

    Measured: up to 12 months

  2. To assess general demographic characteristics of patients with ATTR PN in Russia: Mean age (years) at the onset of polyneuropathy symptoms

    Measured: up to 12 months

  3. to assess general demographic characteristics of patients with ATTR PN in Russia: Proportion of patients with late (>50 years) diagnosis of ATTR PN

    Measured: up to 12 months

  4. to assess general demographic characteristics of patients with ATTR PN in Russia: Mean age (years) at the time of CTS surgery

    Measured: up to 12 months

  5. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Number and proportion of patients with specific characteristics of the first and repeat CTS surgery

    1. Left hand;
    2. Right hand;
    3. Both hands;

    Measured: up to 12 months

  6. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients with CTS recurrence after surgery

    Measured: up to 12 months

  7. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients undergoing repeat surgery for CTS after the index operation

    Measured: up to 12 months

  8. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients with PN progression after surgery

    Measured: up to 12 months

  9. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Proportion of patients with different number of red flags:

    1. 1 red flag;
    2. 2 red flags;
    3. 3 red flags;
    4. 4-5 red flags;
    5. 6-10 red flags;
    6. >10 red flags;

    Measured: up to 12 months

  10. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Mean age (years) at ATTR PN diagnosis

    Measured: up to 12 months

  11. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of women and men

    Measured: up to 12 months

  12. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Mean body mass index (BMI) and proportion of patients with different BMI dimensions at the time of CTS diagnosis and at Visit 1:

    1. Underweight (BMI <18.5 kg/m2);
    2. Normal weight (BMI ≥18.5 and <25 kg/m2);
    3. Overweight (BMI ≥25 and <30 kg/m2);
    4. Obesity (BMI ≥30 kg/m2)

    Measured: up to 12 months

  13. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients with a history of unexplained weight loss (≥5 kg) at any point since CTS diagnosis

    Measured: up to 12 months

  14. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Mean and median time from CTS symptom onset (months) to ATTR PN diagnosis

    Measured: up to 12 months

  15. To assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Median number of physicians seen since symptom onset before the correct ATTR PN diagnosis

    Measured: up to 12 months

  16. To assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Median number of hospitalizations for PN before the correct ATTR PN diagnosis

    Measured: up to 12 months

  17. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Number and proportion of patients with previously established incorrect diagnosis according to medical records, specifically with:

    1. CIDP;
    2. Lumbar/sacral radiculopathy;
    3. Lumbar canal stenosis;
    4. Paraproteinaemic peripheral neuropathy;
    5. Chronic progressive sensory/sensorimotor axonal idiopathic PN;
    6. AL amyloidosis;
    7. Fibromyalgia;
    8. Other (specify)

    Measured: up to 12 months

  18. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN: Proportion of patients with family history of neuropathic disease

    Measured: up to 12 months

  19. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN: Proportion of patients with specific peripheral neurological manifestations:

    1. Neuropathic pain (allodynia, hyperalgesia);
    2. Progressive sensory disturbances (loss of temperature, pain, other sensation);
    3. Paresthesia, dysesthesia;
    4. Progressive motor disturbances;
    5. Walking difficulty, gait disorder;
    6. Balance disorder

    Measured: up to 12 months

  20. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN: Proportion of patients with specific Polyneuropathy Disability (PND) classes:

    1. 0;
    2. I;
    3. II;
    4. IIIA;
    5. IIIB;
    6. IV;

    Measured: up to 12 months

  21. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Proportion of patients with specific distribution of polyneuropathy symptoms:

    1. Upper-limb;
    2. Lower-limb;
    3. Both upper-limb and lower-limb

    Measured: up to 12 months

  22. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with autonomic neurological manifestations, including specifically:

    1. Orthostatic hypotension;
    2. Syncope;
    3. Gastrointestinal motility disorders - i. Constipation; ii. Early satiety; iii. Diarrhea; iv. Nausea, vomiting;
    4. Erectile dysfunction;
    5. Neurogenic bladder;
    6. Recurrent urinary infections;
    7. Anhidrosis;

    Measured: up to 12 months

  23. To describe data on the presence of cardiovascular, neurological and other comorbidities- Number and proportion of patients taking specific groups of cardiovascular medications at the time of CTS diagnosis and at the time of prospective visit:

    1. Left ventricular hypertrophy;
    2. Left bundle branch block;
    3. Atrioventricular block;
    4. Heart failure with preserved ejection fraction;
    5. Elevated serum N-terminal-proB-type natriuretic peptide (NT-proBNP) concentration;
    6. Cardiac valve stenosis;
    7. Cardiac valve regurgitation;
    8. Tachyarrhythmia;
    9. Other (specify);
    10. None;

    Measured: up to 12 months

  24. Number of patients taking specific groups of cardiovascular medications at the time of CTS surgery and at the time of prospective visit:

    1. Angiotensin converting enzyme inhibitor (ACEI) (specify);
    2. Angiotensin receptor blocker (ARB) (specify);
    3. Angiotensin receptor and neprilysin inhibitor (ARNI);
    4. Sodium-glucose transporter type 2 inhibitor (SGLT2i) (specify);
    5. Mineralocorticoid receptor antagonist (MRA) (specify);
    6. Beta-blocker (specify);
    7. Diuretic (specify);
    8. Other cardiovascular (CV) medications (specify);
    9. Other (specify);

    Measured: up to 12 months

  25. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with concomitant ophthalmologic manifestations, including specifically

    1. Vitreous body inclusions (opacification);
    2. Glaucoma;
    3. Abnormal conjunctival vessels;
    4. Papillary abnormalities;
    5. Dry eye;
    6. Other (specify);

    Measured: up to 12 months

  26. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with concomitant musculoskeletal manifestations, including specifically:

    1. Spinal stenosis;
    2. Osteoarthritis, including hip and knee arthroplasty;
    3. Trigger finger;
    4. Charcot's joints;
    5. Biceps tendon rupture;
    6. Rotator cuff injury;
    7. Other (specify);

    Measured: up to 12 months

  27. Mean and median serum NT-proBNP (pg/ml) concentration

    Measured: up to 12 months

  28. Proportion of patients with laboratory confirmed paraproteinemia

    Measured: up to 12 months

  29. Mean and median urine albumin-creatinine ratio (UACR, mg/g of creatinine)

    Measured: up to 12 months

  30. Proportion of patients with diagnosed CKD, including specifically

    1. Stage C1;
    2. Stage C2;
    3. Stage C3a;
    4. Stage C3b;
    5. Stage C4;
    6. Stage C5;

    Measured: up to 12 months

  31. Number of patients with concomitant renal dysfunction, including specifically

    1. Elevated SCr level (based on the local laboratory reference range);
    2. Decreased eGFR (<60 ml/min/1.73m2);
    3. Presence of albuminuria (≥30 mg/g creatinine (≥30 mg/g of creatinine or ≥30 mg/24h);
    4. Presence of proteinuria (according to urinalysis results);
    5. Ultrasound signs of amyloid nephropathy;

    Measured: up to 12 months

  32. Number of patients with confirmed length-dependent peripheral sensory-motor neuropathy based on NCS results

    Measured: up to 12 months

  33. Mean and median measured peripheral sensory nerve conduction velocities

    1. Left Medial;
    2. Left Ulnar;
    3. Left Sural;
    4. Right Medial;
    5. Right Ulnar;
    6. Right Sural;

    Measured: up to 12 months

  34. Number of patients with reduced peripheral sensory nerve conduction velocity at ≥1 site

    Measured: up to 12 months

  35. Mean and median measured peripheral motor nerve conduction velocities

    1. Left Medial;
    2. Left Ulnar;
    3. Left Tibial;
    4. Left Peroneal;
    5. Right Medial;
    6. Right Ulnar;
    7. Right Tibial;
    8. Right Peroneal;

    Measured: up to 12 months

  36. Number of patients with reduced motor sensory nerve conduction velocity at ≥1 site

    Measured: up to 12 months

  37. Mean and median measured sensory action potential (SAP) amplitudes

    1. Left Medial;
    2. Left Ulnar;
    3. Left Sural;
    4. Right Medial;
    5. Right Ulnar;
    6. Right Sural

    Measured: up to 12 months

  38. Number of patients with reduced/absent SAP amplitude at ≥1 site

    Measured: up to 12 months

  39. Mean and median measured distal compound muscle action potential (dCMAP) amplitudes

    1. Left Medial;
    2. Left Ulnar;
    3. Left Tibial;
    4. Left Peroneal;
    5. Right Medial;
    6. Right Ulnar;
    7. Right Tibial;
    8. Right Peroneal

    Measured: up to 12 months

  40. Mean and median measured proximal compound muscle action potential (pCMAP) amplitudes

    1. Left Medial;
    2. Left Ulnar;
    3. Left Tibial;
    4. Left Peroneal;
    5. Right Medial;
    6. Right Ulnar;
    7. Right Tibial;
    8. Right Peroneal

    Measured: up to 12 months

  41. Number of patients with reduced/absent dCMAP amplitude at ≥1 site

    Measured: up to 12 months

  42. Number of patients with reduced/absent pCMAP amplitude at ≥1 site

    Measured: up to 12 months

  43. Proportion of patients with each score by each parameter of neurological examination

    Measured: up to 12 months

  44. Number of patients in the specific categories of the modified Rankin scale

    1. Score 1 (no significant disability);
    2. Score 2 (slight disability);
    3. Score 3 (moderate disability);
    4. Score 4 (moderately severe disability);
    5. Score 5 (severe disability);

    Measured: up to 12 months

  45. Proportion of patients with specific number of points according to Inflammatory Neuropathy Cause and Treatment (INCAT) upper extremity scale

    1. 0 points;
    2. 1 point;
    3. 2 points;
    4. 3 points;
    5. 4 points;
    6. 5 points

    Measured: up to 12 months

  46. Median number of points according to INCAT upper extremity scale

    Measured: up to 12 months

  47. Proportion of patients with specific number of points according to INCAT lower extremity scale

    1. 0 points;
    2. 1 point;
    3. 2 points;
    4. 3 points;
    5. 4 points;
    6. 5 points

    Measured: up to 12 months

  48. Median number of points according to INCAT lower extremity scale

    Measured: up to 12 months

  49. Mean and median number of points according to combined clinical and electrophysiological score

    Measured: up to 12 months

  50. To describe data on the results of genetic testing for ATTR in CTS patients undergoing surgery:Number and proportion of patients with specific TTR gene mutations

    1. Val30Met;
    2. Ile107Val;
    3. Phe33Leu;
    4. Ala81Val;
    5. Ser23Asn;
    6. Ala25Thr;
    7. Val32Ala;
    8. Thr40Asn;
    9. Gly47Ala;
    10. Glu54Gln;
    11. Tyr69Phe;
    12. Glu92Lys;
    13. Thr119Met;
    14. Other

    Measured: up to 12 months

  51. to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Proportion of patients with previously established incorrect diagnosis according to medical records, specifically with:

    1. CIDP;
    2. Lumbar/sacral radiculopathy;
    3. Lumbar canal stenosis;
    4. Paraproteinaemic peripheral neuropathy;
    5. Chronic progressive sensory/sensorimotor axonal idiopathic PN;
    6. AL amyloidosis;
    7. Fibromyalgia;
    8. Other (specify);

    Measured: up to 12 months

  52. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with autonomic neurological manifestations, including specifically:

    manifestations, including specifically:

    1. Orthostatic hypotension;
    2. Syncope;
    3. Gastrointestinal motility disorders - i. Constipation; ii. Early satiety; iii. Diarrhea; iv. Nausea, vomiting;
    4. Erectile dysfunction;
    5. Neurogenic bladder;
    6. Recurrent urinary infections;
    7. Anhidrosis;

    Measured: up to 12 months

  53. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with concomitant cardiac manifestations, including specifically:

    1. Left ventricular hypertrophy;
    2. Left bundle branch block;
    3. Atrioventricular block;
    4. Heart failure with preserved ejection fraction;
    5. Elevated serum N-terminal-proB-type natriuretic peptide (NT-proBNP) concentration;
    6. Cardiac valve stenosis;
    7. Cardiac valve regurgitation;
    8. Tachyarrhythmia;
    9. Other (specify);
    10. None;

    Measured: up to 12 months

  54. proportion of patients taking specific groups of cardiovascular medications at the time of CTS surgery and at the time of prospective visit:

    1. Angiotensin converting enzyme inhibitor (ACEI) (specify);
    2. Angiotensin receptor blocker (ARB) (specify);
    3. Angiotensin receptor and neprilysin inhibitor (ARNI);
    4. Sodium-glucose transporter type 2 inhibitor (SGLT2i) (specify);
    5. Mineralocorticoid receptor antagonist (MRA) (specify);
    6. Beta-blocker (specify);
    7. Diuretic (specify);
    8. Other cardiovascular (CV) medications (specify);
    9. Other (specify);

    Measured: up to 12 months

  55. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with concomitant ophthalmologic manifestations, including specifically

    1. Vitreous body inclusions (opacification);
    2. Glaucoma;
    3. Abnormal conjunctival vessels;
    4. Papillary abnormalities;
    5. Dry eye;
    6. Other (specify);

    Measured: up to 12 months

  56. To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with concomitant musculoskeletal manifestations, including specifically:

    1. Spinal stenosis;
    2. Osteoarthritis, including hip and knee arthroplasty;
    3. Trigger finger;
    4. Charcot's joints;
    5. Biceps tendon rupture;
    6. Rotator cuff injury;
    7. Other (specify);

    Measured: up to 12 months

  57. proportion of patients with concomitant renal dysfunction, including specifically

    1. Elevated SCr level (based on the local laboratory reference range);
    2. Decreased eGFR (<60 ml/min/1.73m2);
    3. Presence of albuminuria (≥30 mg/g creatinine (≥30 mg/g of creatinine or ≥30 mg/24h);
    4. Presence of proteinuria (according to urinalysis results);
    5. Ultrasound signs of amyloid nephropathy;

    Measured: up to 12 months

  58. proportion of patients with confirmed length-dependent peripheral sensory-motor neuropathy based on NCS results

    Measured: up to 12 months

  59. proportion of patients with reduced peripheral sensory nerve conduction velocity at ≥1 site

    Measured: up to 12 months

  60. proportion of patients with reduced motor sensory nerve conduction velocity at ≥1 site

    Measured: up to 12 months

  61. proportion of patients with reduced/absent SAP amplitude at ≥1 site

    Measured: up to 12 months

  62. proportion of patients with reduced/absent dCMAP amplitude at ≥1 site

    Measured: up to 12 months

  63. proportion of patients with reduced/absent pCMAP amplitude at ≥1 site

    Measured: up to 12 months

  64. proportion of patients in the specific categories of the modified Rankin scale

    -a) Score 1 (no significant disability); b) Score 2 (slight disability); c) Score 3 (moderate disability); d) Score 4 (moderately severe disability); e) Score 5 (severe disability

    Measured: up to 12 months

  65. To assess general demographic characteristics of patients with ATTR PN in Russia - Mean age (years) at the primary CTS diagnosis

    Measured: up to 12 months

  66. To assess general demographic characteristics of patients with ATTR PN in Russia - Mean age (years) at the identification of bilateral involvement

    Measured: up to 12 months

  67. To assess general demographic characteristics of patients with ATTR PN in Russia - Mean age (years) at ATTR PN diagnosis

    Measured: up to 12 months

  68. To assess general demographic characteristics of patients with ATTR PN in Russia -Proportion of patients underwent CTS surgery (i.e. at least one surgery)

    Measured: up to 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 May 2024
  2. Study start29 Dec 2023
  3. Primary completion12 Jun 2025
  4. Study completion12 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
721 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06414746
Sponsor's protocol ID
D8451R00001
Acronym
LOCUS
Status last verified
Apr 2026
First submitted
16 Feb 2024
Last updated
4 Jun 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in